openPR Logo
Press release

Stem Cells in new spinal cord paraplegia study showing improvements

11-27-2017 11:21 AM CET | Health & Medicine

Press release from: MD Stem Cells

Stem Cells in new spinal cord paraplegia study showing

MD Stem Cells reports initial results of their new study in paraplegia using Bone Marrow Derived Stem Cells (BMSC) have shown a prompt improvement in sensory function. The Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality (SciExVR) study is an Institutional Review Board approved, patient sponsored clinical study registered with the National Institutes of Health (NIH) NCT 03225625. It uses a multi-injection and application approach of BMSC for patients with Thoracic and Lumbar spinal cord injuries or disease with motor, sensory and/or bowel-bladder dysfunction. In addition to the BMSC applications, arms include exoskeleton use and virtual reality use to further stimulate the motor and sensory neurons of the brain.
“We are excited that at the 1 month post- SciExVR visit our initial patient showed recovery of neurologic sensation - from 1 to 2 spinal cord segments improved from the original loss of function level. This was on the American Spinal Injury Association (ASIA) Injury Assessment (AIA) measured by the patient’s own physician at his rehabilitation facility pre and post-treatment” indicated Dr. Steven Levy MD, CEO of MD Stem Cells and Study Director for the SciExVR study. “It is likely that the paraspinal multi-injection of BMSC at, above and below the spinal cord injury level, combined with BMSC given intravenously and intranasally, is positively affecting the sensory cells in the dorsal roots and their associated ascending fibers”.
The American Spinal Injury Association is the leading organization in spinal cord injury and care in North America. The ASIA Injury Assessment is a comprehensive, reproducible test of sensory functions such as light touch and pin prick, as well as motor function meaning strength and movement of muscles. The exact level of impairment can be determined and any changes noted over time.
In the SciExVR study mesenchymal and other stem cells are separated from the bone marrow using an FDA cleared medical device and in full compliance with FDA guidelines on use of these stem cells. The procedure is performed in a fully licensed surgical center with board certified anesthesiology support by a fellowship trained spinal surgeon. In addition to the application of the stem cells in separate paraspinal locations, intravenous and intranasal- arms 2 and 3 are designed to potentially increase motor neuron stimulation with the hope this will encourage neuronal transdifferentiation of the BMSC. Arm 2 allows patients to use motorized external support for walking which is called an Exoskeleton and is increasingly available at rehabilitation facilities across the country. Arm 3 uses Virtual Reality exposure to similarly stimulate motor and sensory cells.
MD Stem Cells believes improvements in motor function may take at least a year to occur. Early neuroglial cell reformation, exosomal release of neurotrophic factors and mitochondrial transfer may offer initial motor recovery in neurons that are still partially viable. The ultimate goal is reconnection of transected or injuried upper motor neurons to the lower motor neurons through bridging neurons. The belief is that the brain will relearn and adjust control of any new motor and sensory reconnections which may not match the original pre-injury pathways.
“There is certainly evidence in the scientific literature of BMSC undergoing neuronal transdifferentiation in the Central Nervous System (CNS). In our own study in ophthalmology called the Stem Cell Ophthalmology Treatment Study (SCOTS) we have evidence of CD34 marked bone marrow stem cells transdiffentiating into NeuN+ cells which are neurons” remarked Dr. Levy. “We are cautiously optimistic that the same can occur along the length of the spinal cord and benefit paraplegia.”
Patients with thoracic or lumber spinal cord disease or injuries may contact Dr. Levy for more information on the SciExVR study. stevenlevy@mdstemcells.com 203-423-9494.

MD Stem Cells is a trusted and valued source of the latest information regarding clinically available adult stem cell treatments for patients. MD Stem Cells coordinates patient referrals and manages the treatment process for patients and providers.

MD Stem Cells
Steven Levy MD, CEO
3 Sylvan Road South
Westport, CT 06880
stevenlevy@mdstemcells.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Stem Cells in new spinal cord paraplegia study showing improvements here

News-ID: 832509 • Views: 822

More Releases from MD Stem Cells

New treatment shows vision benefit in Age Related Macular Degeneration
MD Stem Cells reports dry AMD results from their clinical study SCOTS- the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up. No complications occurred. ============================================================================== Age Related Macular Degeneration- specifically dry AMD- will affect almost 200 million people world-wide in 2020. An approach, pioneered by MD Stem Cells, using bone marrow stem
Dr. Steven Levy, CEO of MD Stem Cells, joins editorial board of Clinical Trials …
MD Stem Cells announces that the company’s President and CEO, Steven Levy MD, has joined the editorial board of Clinical Trials in Degenerative Diseases (CTDD). In addition to his role as executive officer for MD Stem Cells, Dr. Levy is Study Director for several pivotal stem cell clinical trials using autologous bone marrow derived stem cells. These including SCOTS –the Stem Cell Ophthalmology Treatment Study (NCT 0192086) ,

More Releases for Cell

Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports. This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions. This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer. Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u Top Key Players: - Becton, Dickinson and Company Biospherix EMD Millipore Eppendorf AG Merck KGaA Sartorius AG VWR International Cell culture is a rapidly emerging
Cell Therapy Market Cell Therapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Cell Therapy Necessity for Cell Therapy Treatment 2.1 Emergence of Stem Cell Research 2.2 Benefits of Using the Stem Cell for Research and Treatment Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent Stem Cells 3.1.3 Multipotent
Global Cell Therapy Market & Cell Therapy Clinical Pipeline Outlook 2022
The cell therapy industry is rapidly growing industry with the several new products that having been accepted for clinical use over the past few years. There are many challenges that need to be resolved wisely before the cell therapies are widely accepted, including the optimization of their manufacture. There is much to be explored about the specific features of the stem cells and about the efficacy and safety of the
Cell Science 2017
It takes us immense pleasure to announce the conference that “Annual Congress on Cell Science, Stem Cell Research & Regenerative Medicine” which is going to be held during November 29-30, 2017 at Atlanta, USA. Cell Science 2017 conference will focus on the latest and exciting innovations in all areas of Cell Biologists and Stem Cell Researchers which offer a unique opportunity for investigators across the globe to meet, network, and perceive
Cell Science 2017
Pulsus Group is an internationally renowned medical peer-review publisher and conferences organizer established in the year 1984 publishes and hosts the work of researchers in a manner that exemplifies the highest standards in research integrity.With a legacy of 30 years of excellence in Medical Publishing we are endorsed by various societies like International Academy of Cardiovascular Sciences, International Society of Addiction Medicine, European Biotechnology Thematic Network Association, World Federation of